CO2020004831A2 - Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa - Google Patents
Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativaInfo
- Publication number
- CO2020004831A2 CO2020004831A2 CONC2020/0004831A CO2020004831A CO2020004831A2 CO 2020004831 A2 CO2020004831 A2 CO 2020004831A2 CO 2020004831 A CO2020004831 A CO 2020004831A CO 2020004831 A2 CO2020004831 A2 CO 2020004831A2
- Authority
- CO
- Colombia
- Prior art keywords
- administration
- treatment
- antibodies
- patients
- dosage
- Prior art date
Links
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 title abstract 3
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568060P | 2017-10-04 | 2017-10-04 | |
| US201862652615P | 2018-04-04 | 2018-04-04 | |
| PCT/US2018/053976 WO2019070714A1 (en) | 2017-10-04 | 2018-10-02 | ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020004831A2 true CO2020004831A2 (es) | 2020-05-29 |
Family
ID=64051671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0004831A CO2020004831A2 (es) | 2017-10-04 | 2020-04-20 | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200262897A1 (enExample) |
| EP (2) | EP3692064A1 (enExample) |
| JP (2) | JP2020536097A (enExample) |
| KR (1) | KR20200059279A (enExample) |
| CN (1) | CN111278857A (enExample) |
| AU (1) | AU2018345625A1 (enExample) |
| BR (1) | BR112020006692A2 (enExample) |
| CA (1) | CA3078362A1 (enExample) |
| CO (1) | CO2020004831A2 (enExample) |
| MX (1) | MX2020003619A (enExample) |
| WO (1) | WO2019070714A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| WO2019227102A1 (en) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| EP3856164B1 (en) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| US12239645B2 (en) | 2018-12-17 | 2025-03-04 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| JP7635138B2 (ja) | 2019-03-22 | 2025-02-25 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| JP2022542430A (ja) * | 2019-08-01 | 2022-10-03 | ヤンセン バイオテツク，インコーポレーテツド | Ｆｃｒｎ抗体およびその使用の方法 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| RS64039B1 (sr) * | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| PE20240825A1 (es) * | 2016-06-17 | 2024-04-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y metodos de uso |
-
2018
- 2018-10-02 EP EP18796165.1A patent/EP3692064A1/en not_active Withdrawn
- 2018-10-02 JP JP2020519138A patent/JP2020536097A/ja active Pending
- 2018-10-02 CN CN201880065034.5A patent/CN111278857A/zh active Pending
- 2018-10-02 EP EP24174774.0A patent/EP4424324A3/en active Pending
- 2018-10-02 US US16/651,520 patent/US20200262897A1/en not_active Abandoned
- 2018-10-02 BR BR112020006692-3A patent/BR112020006692A2/pt not_active IP Right Cessation
- 2018-10-02 MX MX2020003619A patent/MX2020003619A/es unknown
- 2018-10-02 WO PCT/US2018/053976 patent/WO2019070714A1/en not_active Ceased
- 2018-10-02 CA CA3078362A patent/CA3078362A1/en not_active Abandoned
- 2018-10-02 AU AU2018345625A patent/AU2018345625A1/en not_active Abandoned
- 2018-10-02 KR KR1020207012177A patent/KR20200059279A/ko not_active Withdrawn
-
2020
- 2020-04-20 CO CONC2020/0004831A patent/CO2020004831A2/es unknown
-
2023
- 2023-02-28 US US18/115,226 patent/US20240025975A1/en active Pending
- 2023-05-31 JP JP2023089908A patent/JP2023101717A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018345625A1 (en) | 2020-04-16 |
| US20200262897A1 (en) | 2020-08-20 |
| WO2019070714A1 (en) | 2019-04-11 |
| JP2020536097A (ja) | 2020-12-10 |
| JP2023101717A (ja) | 2023-07-21 |
| EP3692064A1 (en) | 2020-08-12 |
| US20240025975A1 (en) | 2024-01-25 |
| CN111278857A (zh) | 2020-06-12 |
| EP4424324A2 (en) | 2024-09-04 |
| BR112020006692A2 (pt) | 2020-10-06 |
| CA3078362A1 (en) | 2019-04-11 |
| EP4424324A3 (en) | 2024-11-06 |
| MX2020003619A (es) | 2020-10-28 |
| KR20200059279A (ko) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
| CO2020004838A2 (es) | Dosis y administración de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxística nocturna (hpn) y el síndrome hemolítico urémico atípico (shua) | |
| JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
| MX2021008919A (es) | Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua). | |
| EP3689909A4 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
| PH12019502361A1 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| IL285923A (en) | Compositions, methods, and kits for delivery of polyribonucleotides | |
| ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| EA201692436A1 (ru) | Медицинское применение | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| CY1123982T1 (el) | Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) | |
| JO3537B1 (ar) | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة | |
| EA202091989A1 (ru) | Способы лечения язвенного колита | |
| EA201790475A1 (ru) | Способы лечения системной красной волчанки с использованием доменного антитела против cd28 | |
| MX2017002382A (es) | Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| MX2021009789A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de miastenia gravis generalizada. | |
| DK3394045T3 (da) | Co-krystal, fremstillingsfremgangsmåde deraf og medikament som indeholder co-krystal. | |
| HUE063119T2 (hu) | Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez | |
| MX2019007107A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. | |
| MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. |